Home

Johnson & Johnson (JNJ)

154.01
+0.52 (0.34%)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products

The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world.

SummaryNewsPress ReleasesChartHistoricalFAQ
Previous Close153.49
Open153.82
Bid153.94
Ask154.01
Day's Range153.31 - 154.15
52 Week Range140.68 - 168.85
Volume1,040,994
Market Cap404.84B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield4.960 (3.22%)
1 Month Average Volume9,891,948

News & Press Releases

What To Expect From Eli Lilly’s (LLY) Q4 Earnings
Global pharmaceutical company Eli Lilly (NYSELLY) will be reporting results tomorrow morning. Here’s what to expect.
Via StockStory · February 5, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
BALA CYNWYD, Pa., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · February 4, 2025
Can Biotech Stocks Survive The Precarious Macro?talkmarkets.com
We were having a nice rally in January 2025 until the reality of tariffs hit on Friday which killed the momentum developing off the mid-January lows.
Via Talk Markets · February 3, 2025
Is Johnson & Johnson Stock a Buy?fool.com
Via The Motley Fool · February 2, 2025
Johnson & Johnson's Options Frenzy: What You Need to Knowbenzinga.com
Via Benzinga · January 30, 2025
Johnson & Johnson to Participate in the 45th Annual TD Cowen Healthcare Conference
Johnson & Johnson (NYSEJNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · February 3, 2025
Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now
Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?
Via MarketBeat · February 3, 2025
Johnson & Johnson Announces a Major Acquisition. Can It Turn the Stock's Fortunes Around?fool.com
Via The Motley Fool · February 1, 2025
Did Johnson & Johnson Just Give Investors 23 Billion Reasons to Buy Its Stock?fool.com
Via The Motley Fool · February 1, 2025
Johnson & Johnson (NYSE:JNJ) Posts Q4 Sales In Line With Estimates
Multinational healthcare company Johnson & Johnson (NYSEJNJ) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion. Its non-GAAP profit of $2.04 per share was 1.3% above analysts’ consensus estimates.
Via StockStory · January 31, 2025
The Dogs Of The Dow 2025talkmarkets.com
The Dogs of the Dow is an investing strategy well-known to retail and institutional investors.
Via Talk Markets · January 31, 2025
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Ordersbenzinga.com
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
Via Benzinga · January 29, 2025
Starbucks To Rally Over 23%? Here Are 10 Top Analyst Forecasts For Wednesdaybenzinga.com
Via Benzinga · January 29, 2025
Marjorie Taylor Greene Loads Up On Meta, Amazon, Tesla, Nvidia And Other Stocks As Donald Trump's New Equations With Big Tech Leaders Sets Stage For Growth: What Is At Stake?benzinga.com
U.S. House Representative Marjorie Taylor Greene has disclosed new trades as Donald Trump's equations evolves with Big Tech leaders.
Via Benzinga · January 29, 2025
Georgia Rep. Marjorie Taylor Greene Bought Up to $45K Worth of Johnson & Johnson Stockbenzinga.com
Via Benzinga · January 28, 2025
3 Stocks Upgraded by Bank of America – Here's Why They're Bullish
Bank of America analysts have recently shifted their views on these three stocks, leaving investors with a few points to consider.
Via MarketBeat · January 28, 2025
McDonald's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesdaybenzinga.com
Via Benzinga · January 28, 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Logility Supply Chain Solutions, Inc. (Nasdaq - LGTY), Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Shutterstock, Inc. (NYSE - SSTK)
BALA CYNWYD, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
By Brodsky & Smith LLC · Via GlobeNewswire · January 27, 2025
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · January 27, 2025
These Were the 5 Worst-Performing Stocks in the Dow Jones Industrial Average in 2024fool.com
Via The Motley Fool · January 25, 2025
Why Traders Are Buying the Dip on Johnson & Johnson Stock
Shares of Johnson & Johnson stock have declined by 11.5% in the quarter, and markets are calling for a bottom and rally here.
Via MarketBeat · January 25, 2025
5 of the Safest High-Yield Dividend Stocks You Can Confidently Buy for 2025fool.com
Five magnificent income stocks -- sporting an average yield of 4.26% -- can pad investors' pocketbooks in the new year (and well beyond).
Via The Motley Fool · January 24, 2025
Up About 62% in a Year, Can Intuitive Surgical Stock Keep Soaring?fool.com
Via The Motley Fool · January 23, 2025
Stocks Going Ex Dividend In February 2025talkmarkets.com
This article features a short list of some of the many stocks going ex-dividend during the next month, which can be helpful for traders and investors
Via Talk Markets · January 24, 2025
Abbott Laboratories Will Outperform Healthcare Stocks in 2025
Johnson & Johnson and Abbott Laboratories offer substantial opportunities for investors, but one is a better buy for total returns in 2025 and 2026.
Via MarketBeat · January 24, 2025